- Conditions
- Cancer
- Interventions
- Dabrafenib, Trametinib
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Santa Monica, California • Bethesda, Maryland + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–46
of 22
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Interventions
- Plixorafenib
- Drug
- Lead sponsor
- Fore Biotherapeutics
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 254 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 30
- States / cities
- Beverly Hills, California • San Francisco, California • Westwood, Los Angeles, California + 22 more
- Conditions
- Brain Cancer, HGG, Glioma, High Grade Glioma, High Grade Gliomas, High Grade Glioma (III or IV), High Grade Glioma (HGG) of the Brain With BRAF Aberration
- Interventions
- Nivolumab, Nivolumab-IRDye800
- Drug
- Lead sponsor
- Eben Rosenthal
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Glioma, Malignant, Surgery, Seizures
- Interventions
- Perampanel, Standard of Care
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Malignant Glioma
- Interventions
- Capecitabine
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- High Grade Glioma
- Interventions
- SONALA-001(ALA) and MR-Guided Focused Ultrasound device (MRgFUS), MR-Guided Focused Ultrasound device (MRgFUS)
- Combination Product · Device
- Lead sponsor
- Nader Sanai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Bithalamic High Grade Glioma
- Interventions
- Ribociclib
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 12 Months to 30 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- High-Grade Glioma
- Interventions
- CLR 131
- Drug
- Lead sponsor
- Cellectar Biosciences, Inc.
- Industry
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 7
- States / cities
- Palo Alto, California • New York, New York • Cincinnati, Ohio + 4 more
- Conditions
- High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Gliosarcoma, Glioblastoma
- Interventions
- Encorafenib, Binimetinib, Research Bloods, Tumor Tissue
- Drug · Biological
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Baltimore, Maryland • Winston-Salem, North Carolina
- Conditions
- Malignant Glioma
- Interventions
- Biopsy Procedure, Magnetic Resonance Imaging, Radiation Therapy, Selinexor
- Procedure · Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 109
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 91 more
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Interventions
- Toca 511 vector, Toca FC
- Biological · Drug
- Lead sponsor
- Tocagen Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Diego, California • Detroit, Michigan + 5 more
- Conditions
- Glioblastoma, High-Grade Glioma (WHO III-IV), High-grade Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Hemispheric Glioma, H3G34 Mutant
- Interventions
- ADI-PEG 20 (Arginine deiminase pegylated), Temozolomide (TMZ), Standard of Care Radiation Therapy (RT)
- Drug · Radiation
- Lead sponsor
- Sabine Mueller, MD, PhD
- Other
- Eligibility
- 3 Years to 39 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2035
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Glioblastoma, Malignant Glioma, Brain Tumors, Anaplastic Astrocytoma
- Interventions
- Stem Cell Radiotherapy (ScRT) and Temozolomide
- Radiation
- Lead sponsor
- Beth Israel Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diffuse Intrinsic Pontine Glioma, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Medulloblastoma
- Interventions
- Fimepinostat, Therapeutic Conventional Surgery
- Drug · Procedure
- Lead sponsor
- Sabine Mueller, MD, PhD
- Other
- Eligibility
- 3 Years to 39 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 18
- States / cities
- Los Angeles, California • San Diego, California • San Francisco, California + 15 more
- Conditions
- Glioma, High Grade Glioma, Glioma, Malignant, Glioma Intracranial, Diffuse Glioma
- Interventions
- 18F-Fluciclovine PET-MRI
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent High Grade Glioma
- Interventions
- Treatment with CD200AR-L
- Drug
- Lead sponsor
- OX2 Therapeutics
- Industry
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High Grade Glioma
- Interventions
- Dendritic Cell Vaccine, Tumor Lysate, Imiquimod, Leukapheresis
- Biological · Drug · Procedure
- Lead sponsor
- Macarena De La Fuente, MD
- Other
- Eligibility
- 13 Years to 99 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- High Grade Glioma
- Interventions
- Trans Sodium Crocetinate (TSC)
- Drug
- Lead sponsor
- Diffusion Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
- Interventions
- Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture, Magnetic Resonance Imaging, Radiation Therapy, Trametinib Dimethyl Sulfoxide
- Procedure · Drug · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 106 more
- Conditions
- Fatigue
- Interventions
- Clinic-based physical therapy program., Home exercise program.
- Other
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma
- Interventions
- Radiation Therapy, Temozolomide, Veliparib
- Radiation · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 145
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 111 more
- Conditions
- Diffuse Intrinsic Pontine Glioma, High-grade Glioma
- Interventions
- Crizotinib, Dasatinib
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee